Ramon “Mon” Tulfo said that he’s willing to face any investigation over Sinopharm inoculation.
Former Special Envoy to China Ramon “Mon” Tulfo on Wednesday said that he was willing to face any investigation over Sinopharm inoculation.
In a report on GMA News Online, Tulfo said that he’s willing to face any investigation and even go to jail over his Sinophram inoculation against COVID-19 last year.
Tulfo told GMA News that he’s willing to face any investigation but they would also investigate those officials who were also inoculated.
When asked if he would identify under oath those government officials he claimed to have also been inoculated, Tulfo replied: “Hindi, hindi, hindi. I’m sorry. Bahala na. Kung mangyari, I’m willing to go to jail.”
According to Tulfo, he got vaccinated last October 2020.
READ ALSO: Ramon Tulfo Clarifies Appointment As Special Envoy To China Had Already Expired
The country’s Food and Drug Administration (FDA) had not yet approved the commercial distribution of any COVID-19 vaccine nor an emergency use authorization (EUA) for the Sinopharm COVID-19 vaccine until now.
What Malacañang announced last February 11 was that the Food and Drug Administration granted Sinopharm “compassionate use” of its COVID-19 vaccines for the Presidential Security Group (PSG) members, long after it was first revealed by President Duterte that some PSG members had been inoculated since last year.
When asked if he knew that the inoculation was illegal, Tulfo replied, “Alam ko. Dahil smuggled din yon eh.”
According to Tulfo, he decided to get inoculated in order to see if the said vaccine was indeed effective against the coronavirus disease (COVID-19) as he’s applying to be its distributor in the Philippines.
When asked if he felt any adverse effects after getting inoculated with China’s Sinopharm COVID-19 vaccine, Tulfo replied, “Wala. Beneficial nga. Walang adverse side effect.”
For more news and updates, you may feel free to visit this site more often. You may also visit Newspapers.ph via our official Facebook page and YouTube channel.